Advances in Lymphoma
Transcript: High-impact data at ESMO 2024
Professor Andrés Ferreri
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So the most interesting data in this meeting in regards to new forms of treatment for patients, in particular, are new forms of radiation therapy. We use an hypofractionated schedule in order to reduce the toxicity, maintaining the efficacy in patient with indolent lymphomas. In a few patient treated with 12 Gy and in four fractions, the overall response rate was 100%, and without toxicity only with grade one, two local effects, which is a very interesting step forward in the radiation therapy in these patients.
Another strategy is the combination of new drugs, in particular, in poor prognosis lymphomas, like for example, relapsed or refractory Hodgkin lymphoma, or peripheral T-cell lymphomas. The need for new drugs and for more investigations, and obviously, all the studies regarding the new developments in CAR T-cell therapy.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event